Short Interest in Interpace Biosciences, Inc. (OTCMKTS:IDXG) Drops By 61.0%

Interpace Biosciences, Inc. (OTCMKTS:IDXG) was the recipient of a significant decrease in short interest in the month of June. As of June 30th, there was short interest totaling 306 shares, a decrease of 61.0% from the June 15th total of 785 shares. Based on an average trading volume of 14,473 shares, the short-interest ratio is currently 0.0 days. Approximately 0.0% of the shares of the stock are sold short.

Interpace Biosciences Stock Performance

Interpace Biosciences stock traded up $0.05 during midday trading on Tuesday, reaching $1.55. The company’s stock had a trading volume of 351 shares, compared to its average volume of 7,499. The firm has a market capitalization of $6.87 million, a PE ratio of -31.00 and a beta of 0.59. Interpace Biosciences has a fifty-two week low of $0.76 and a fifty-two week high of $2.40. The stock’s 50 day simple moving average is $1.74 and its 200 day simple moving average is $1.71.

Interpace Biosciences (OTCMKTS:IDXG) last posted its quarterly earnings results on Tuesday, May 12th. The business services provider reported $0.03 earnings per share for the quarter. Interpace Biosciences had a net margin of 65.25% and a return on equity of 219.07%. The business had revenue of $9.03 million for the quarter.

Interpace Biosciences Company Profile

Interpace Biosciences, Inc provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer.